StockData
ALKSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Alkermes plc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$42.97+1.75 (+4.25%)

Close on Oct 19, 2026

Market cap
$7.45B
P/E (TTM)
113.1
Dividend yield
–

Earnings

Next report expected Oct 27, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 28, 2026Before market open$496.00M––
Q1 FY2026
Ended Mar 31, 2026
May 5, 2026Before market open–––
Q4 FY2025
Ended Dec 31, 2025
Feb 25, 2026Before market open$384.50M$0.29–
Q3 FY2025
Ended Sep 30, 2025
Oct 28, 2025Before market open$394.20M$0.49–
Q2 FY2025
Ended Jun 30, 2025
Jul 29, 2025Before market open$390.70M$0.52–
Q1 FY2025
Ended Mar 31, 2025
May 1, 2025Before market open$306.50M$0.13–
Q4 FY2024
Ended Dec 31, 2024
Feb 12, 2025Before market open$430.00M$0.88$1.04
Q3 FY2024
Ended Sep 30, 2024
Oct 24, 2024Before market open$378.10M$0.55$0.72
Q2 FY2024
Ended Jun 30, 2024
Jul 24, 2024Before market open–––
Q1 FY2024
Ended Mar 31, 2024
May 1, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Feb 15, 2024Before market open–––

Company guidance

Outlook given with results on Feb 25, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
EBITDAnon-GAAP2026$60.00M to $90.00M–
Adjusted EBITDAnon-GAAP2026$370.00M to $410.00M–
Total RevenuesGAAP2026$1.73B to $1.84B–

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Alkermes filed with the SEC